Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 8Sarcoma 2Gynecologic 2Genitourinary 2Dermatologic 2Breast 2Thoracic 1NET 1Head & Neck 1Endocrine 1CNS 1

Conditions

Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Neoplasm Metastasis 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Islet Cell 1

Interventions

Sunitinib 3telotristat ethyl 1romidepsin 1lutetium Lu 177 dotatate 1gallium Ga 68 dotatate 1folfirinox 1fludarabine phosphate 1fludarabine 1entrectinib 1copper dotatate CU-64 1alectinib 1Temozolomide 1TH 302 1Quality of Life 1Poly(ADP-ribose) Polymerase Inhibitors 1Plastic Surgery Procedures 1Patient Reported Outcome Measures 1Needles 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Lutetium-177 1Lutetium 1Lactones 1Immunotherapy 1Granulocyte Colony-Stimulating Factor 1Fluorodeoxyglucose F18 1Filgrastim 1FAPI-46 1Everolimus 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × Filgrastim × NET × Clear all
NCT03042780 2020-11-27

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
2 enrolled 6 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡